by Dr. Paul Karpecki | Dec 1, 2022 | Emerging Technology & Trends, Practice Pearls, Relating to Your Patients
A new therapeutic approach for ptosis Until recently, there were few treatment options besides surgery for patients with ptosis, also known as blepharoptosis or drooping eyelids. That changed in 2020 when the FDA approved Upneeq eye drops (oxymetazoline HCL 1%), which...
by Dr. Paul Karpecki | Sep 6, 2022 | Emerging Technology & Trends, Relating to Your Patients
The first drug for the treatment of geographic atrophy secondary to age-related macular degeneration may be approved this year Geographic atrophy (GA), the chronic progressive degeneration of the macula as part of late-stage age-related macular degeneration (AMD),...
by Dr. Paul Karpecki | Jul 27, 2022 | Feature Spotlight, Practice Pearls
An exciting new drug for dry eye disease will soon be available Several novel and greatly needed ocular surface disease agents are showing promise in FDA trials, projected to be approved for clinic use as soon as next summer. Now is the time to begin educating...
by Dr. Paul Karpecki | May 31, 2022 | Feature Spotlight, Relating to Your Patients, Uncategorized
Diagnosing and treating incomplete lid closure and nocturnal evaporative stress Do you have patients with non-responsive dry eye disease? In many cases, the answer lies not on the cornea or conjunctiva, and it’s not environmental. Rather, it’s the eyelid —...
by Dr. Paul Karpecki | Apr 15, 2022 | Relating to Your Patients
Videos can help patients understand this new treatment option Dry eye therapy has come a long way in recent years, especially since we now know the trigeminal nerve plays a critical role in ocular surface health and symptoms. In June 2020, I wrote about a new...
